ZUBEREITUNG VON BUPRENORPHIN

European patent · EP4090662 · In force

Register entry

Publication number
EP4090662
Application number
EP21701689
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 14, 2021
Published
Nov 23, 2022
Granted
Jun 12, 2024
Protection ends at the latest
Jan 13, 2041
Next annual fee due
Jan 31, 2027
IPC classes
C07D 489/02 (2006.01)
Priority
US 202062962335 P 17.01.2020
PCT application
PCT/EP2021/050692 14.01.2021
PCT publication
WO2021/144362 22.07.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Apr 23, 2025

    Change

    Published in Swissreg on 23.04.2025

  3. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  4. Jan 29, 2025

    Agent’s address changed

    Representative
    Cosmovici Intellectual Property Sàrl, Rue du Commerce 4, 1204 Genève → Cosmovici Intellectual Property, Rue de la Corraterie 5, 1204 Genève

    Published in Swissreg on 29.01.2025

  5. Jul 2, 2024

    Agent entered

    Representative
    Cosmovici Intellectual Property Sàrl, Rue du Commerce 4, 1204 Genève

    Published in Swissreg on 02.07.2024

  6. Jun 12, 2024

    Granted

    Published in Swissreg on 12.06.2024

Parties

Holder

River Stone Biotech ApS

Symbion Science Park Fruebjergvej 3, 2100 Copenhagen, DK

Agent

Cosmovici Intellectual Property

Rue de la Corraterie 5, 1204 Genève

Inventor

SANTELLA, Marco

2100 Copenhagen, DK

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.